Bliss GVS Pharma Declares 100% Dividend, Schedules 41st AGM for July 15, 2026
Bliss GVS Pharma announced audited standalone and consolidated financial results for the year ended March 31, 2026. The company recommended a 100% final dividend (₹1 per share). The 41st AGM is scheduled for July 15, 2026. BDO India Services re-appointed as Internal Auditor.
The declaration of a dividend and the approval of financial results are material events for shareholders, impacting the company's stock.
The company announced positive financial results, recommended a dividend, and scheduled its AGM, all indicating normal and positive corporate activity.
Bliss GVS Pharma Limited announced the outcome of its Board Meeting held on May 12, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the auditors' report, which declared an unmodified opinion.
The company recommended a final dividend of 100%, or ₹1 per equity share, for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming 41st Annual General Meeting (AGM).
The 41st AGM is scheduled to be held on Wednesday, July 15, 2026, at 11:00 AM through Video Conferencing (VC) or Other Audio Visual Means (OAVM). The registered office of the company will be the deemed venue for the AGM.
Additionally, M/s. BDO India Services Private Limited has been re-appointed as the Internal Auditor for the financial year 2026-27. The Board meeting commenced at 5:05 PM and concluded at 7:30 PM.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.